XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 19,397,822 $ 23,786,579
Short-term investments 66,096,567 103,638,844
Accounts receivable 2,831,707 6,003,205
Accounts receivable from affiliated entities 1,567,635 486,619
Prepaid expenses and other current assets 1,601,859 2,600,906
Prepaid expenses and other current assets from affiliated entities 2,107,194 1,846,007
Total current assets 93,602,784 138,362,160
Fixed assets, net 16,228,171 18,320,176
Investment in affiliated entity - GeneOne 9,501,138 9,069,401
Investment in affiliated entity - PLS 3,198,516 2,325,079
Intangible assets, net 5,026,708 6,009,729
Goodwill 10,513,371 10,513,371
Other assets 2,625,659 2,639,354
Total assets 140,696,347 187,239,270
Current liabilities:    
Accounts payable and accrued expenses 17,324,819 23,278,798
Accounts payable and accrued expenses due to affiliated entities 690,920 926,943
Accrued clinical trial expenses 7,353,055 8,611,892
Common stock warrants 0 360,795
Deferred revenue 192,427 1,175,353
Deferred revenue from affiliated entities 68,425 174,110
Deferred rent 1,031,370 877,535
Deferred grant funding 1,297,416 0
Deferred grant funding from affiliated entities 39,583 0
Total current liabilities 27,998,015 35,405,426
Deferred revenue, net of current portion 192,034 215,853
Deferred rent, net of current portion 8,672,689 9,104,416
Deferred tax liabilities 24,766 24,766
Other liabilities 99,669 0
Total liabilities 36,987,173 44,750,461
Stockholders’ equity:    
Preferred stock 0 0
Common stock 94,472 90,358
Additional paid-in capital 690,930,769 665,775,504
Accumulated deficit (587,130,576) (523,356,317)
Accumulated other comprehensive loss (281,760) (117,005)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 103,612,905 142,392,540
Non-controlling interest 96,269 96,269
Total stockholders’ equity 103,709,174 142,488,809
Total liabilities and stockholders’ equity $ 140,696,347 $ 187,239,270